| CONTACTS: |
César García,
President and Chief Executive Officer |
|
818-709-1244 x 7123
|
|
Or
|
|
Ron Stabiner, The Wall Street Group, Inc. |
|
212-888-4848 |
CHATSWORTH, Calif., Sep. 22, 2006
— IRIS International, Inc. (NASDAQ: IRIS)
a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and reference clinical laboratories worldwide, today announced
that President and Chief Executive Officer César García will present an overview of the Company at the UBS Global Life Sciences Conference at 4:30 p.m.
Eastern time on Wednesday, Sept. 27, at the Grand Hyatt Hotel in New York City.
An audio webcast of Mr. García's presentation will be available live and by replay. To access the live webcast, go to
http://events.streamx.us/US/event/EventDetails.aspx?id=ubs20060925.
The link will also be available on the IRIS International, Inc. website at http://www.proiris.com. The replay of the presentation will be posted to the same link three
hours after Mr. García's actual presentation time and will be available until October 28, 2006.
More than 300 executives will make presentations at the three-day conference, which runs from Monday, Sept. 25 through Thursday, Sept.
28. The conference is sponsored by UBS, an investment banking and securities firm and one of the largest asset managers in the world.
The Company
IRIS International, Inc. (http://www.proiris.com), based in Chatsworth, Calif.,
is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit
(formerly the StatSpin® subsidiary) (www.statspin.com), based in Westwood, Mass., manufactures
innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR) (www.adires.com),
based near Houston, Texas, is the Company's imaging research and development subsidiary. The IRIS Molecular Diagnostics (IMD) Subsidiary develops innovative
ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets.
SAFE HARBOR PROVISION
This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, new
product introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes,"
"estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future
performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement.
These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own
knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements. Other factors and uncertainties that could affect
the Company's forward-looking statements include, among other things, the following: identification of feasible new product initiatives, management of R&D
efforts and the resulting successful development of new products and product platforms; acceptance by customers of the Company's products; integration of
acquired businesses; substantial expansion of international sales; reliance on key suppliers; the potential need for changes in long-term strategy in response to
future developments; future advances in diagnostic testing methods and procedures; potential changes in government regulations and healthcare policies, both of which
could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics
and software industries; and competitive factors, including pricing pressures and the introduction by others of new products with similar or better functionality than
our products. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most
recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors
that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise.
